Tag: Generium

Generium is the leading Russian biopharmaceutical company which develops and manufactures pharmaceutical products for the treatment of orphan diseases, cancer, multiple sclerosis, growth hormone deficiency, myocardial infarction and strokes as well as tuberculosis diagnostic test. Generium consists of a high-end R&D center and a fully integrated manufacturing plant.

Russian biotechnological drugs impress interest of the global pharmaceutical community

Madrid became the world capital of the pharmaceutical industry for three days, from 9th to 11th October. The city hosted CPhI Worldwide 2018, the largest international pharmaceutical exhibition.

GENERIUM may start exporting Diaskintest to Iran in the near future

In the near future, GENERIUM plans to start exporting Diaskintest to the Islamic Republic of Iran for its use as one of the main methods for diagnosis of latent and active forms of tuberculosis.

Generium plans to launch manufacturing of Russian-made Tigratest® in 2019

Anna Kuznetsova, the Children's Rights Commissioner for the President of the Russian Federation, visited GENERIUM, a pharmaceutical company. The purpose of the trip was to visit a shop for manufacturi...

GENERIUM signs agreement to supply biotech drugs to Iran

A trilateral agreement between GENERIUM, the leader of Russian biotechnology, BIOSUN PHARMED, an Iranian company, and RSC Pharm, a Russian company, was signed in the Iranian Embassy in Moscow.

Generium selected Goodwin Biotechnology for optimization

International Biotechnology Center "Generium", a private scientific research company in Russia that is committed to developing and delivering innovative, effective, and safe medical products and...

Generium and Shire established a joint venture

Generium, a Russian pharmaceutical company, established a joint venture (SG Biotech) with Shire, an Irish corporation. New partners already control about 70% of the government procurement market of dr...